HLX04

DRUG5 trials

Sponsors

Shanghai Henlius Biotech

Conditions

Advanced Hepatocellular CarcinomaCarcinoma, HepatocellularHealthy Male SubjectsHepatocellular Carcinoma (HCC)Solid Tumor

Phase 1

Pharmacokinetic, Safety and Immunogenicity Phase I Study of HLX04 Versus Avastin® in Healthy Male Subjects

CompletedNCT03483649

Shanghai Henlius BiotechHealthy Male Subjects

Start: 2017-04-21End: 2017-10-29Updated: 2022-05-11

A Phase I Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Anti-PD-1 Antibody (HLX10) in Combination With Avastin Biosimilar (HLX04) in Patients With Advanced Solid Tumors

Shanghai Henlius BiotechSolid Tumor

Start: 2018-11-27End: 2020-12-27Target: 30Updated: 2019-05-23

Phase 2

HLX07 Combination Therapy or Motherapy in Patient With Advanced Hepatocellular Carcinoma

Shanghai Henlius BiotechAdvanced Hepatocellular Carcinoma

Start: 2022-08-01End: 2024-12-15Target: 60Updated: 2022-05-03

A Study to Explore the Reasonable Dosage and Evaluate the Efficacy, Safety and Tolerability of HLX10 and HLX04 with or Without HLX53 in Untreated, Locally Advanced or Metastatic Hepatocellular Carcinoma Patients.

RecruitingNCT06349980

Shanghai Henlius BiotechCarcinoma, Hepatocellular

Start: 2024-08-05End: 2027-02-10Target: 117Updated: 2024-12-18

Phase 3

A Clinical Study to Compare the Efficacy and Safety of HLX10 in Combination With HLX04 Versus Sorafenib as the First-line Treatment in Patients With Locally Advanced or Metastatic HCC

WithdrawnNCT04465734

Shanghai Henlius BiotechHepatocellular Carcinoma (HCC)

Start: 2022-11-15End: 2024-03-15Updated: 2022-05-05

Related Papers

Phase 2 study of serplulimab with the bevacizumab biosimilar HLX04 in the first-line treatment of advanced hepatocellular carcinoma.

2025-01-033 citations

A phase 1 randomized study compare the pharmacokinetics, safety and immunogenicity of HLX04 to reference bevacizumab sourced from the United States, the European Union, and China in healthy Chinese male volunteers.

2021-06-049 citations